TINARI, Nicola
 Distribuzione geografica
Continente #
NA - Nord America 8.369
EU - Europa 5.770
AS - Asia 5.336
SA - Sud America 795
AF - Africa 94
Continente sconosciuto - Info sul continente non disponibili 10
OC - Oceania 9
AN - Antartide 1
Totale 20.384
Nazione #
US - Stati Uniti d'America 8.196
SG - Singapore 2.346
CN - Cina 1.373
IT - Italia 1.155
IE - Irlanda 800
BR - Brasile 640
UA - Ucraina 628
RU - Federazione Russa 607
SE - Svezia 564
VN - Vietnam 559
GB - Regno Unito 492
DE - Germania 465
FR - Francia 459
TR - Turchia 390
IN - India 223
FI - Finlandia 206
HK - Hong Kong 93
CA - Canada 88
BD - Bangladesh 86
NL - Olanda 66
BE - Belgio 62
PL - Polonia 62
MX - Messico 56
AT - Austria 54
JP - Giappone 53
AR - Argentina 52
IQ - Iraq 44
CZ - Repubblica Ceca 41
ZA - Sudafrica 35
ES - Italia 28
LT - Lituania 21
CO - Colombia 20
EC - Ecuador 18
ID - Indonesia 18
PK - Pakistan 18
EG - Egitto 17
UZ - Uzbekistan 17
KR - Corea 14
VE - Venezuela 13
CL - Cile 12
PE - Perù 12
UY - Uruguay 12
AE - Emirati Arabi Uniti 11
SA - Arabia Saudita 11
JM - Giamaica 10
MA - Marocco 10
PY - Paraguay 10
AU - Australia 9
EU - Europa 9
PT - Portogallo 9
GR - Grecia 8
IL - Israele 8
IR - Iran 8
MY - Malesia 8
RO - Romania 8
TN - Tunisia 8
CH - Svizzera 7
JO - Giordania 7
KE - Kenya 7
AL - Albania 6
NP - Nepal 6
PH - Filippine 6
BG - Bulgaria 5
BO - Bolivia 5
DZ - Algeria 5
KZ - Kazakistan 5
LB - Libano 5
TW - Taiwan 5
AZ - Azerbaigian 4
GT - Guatemala 4
HN - Honduras 4
OM - Oman 4
ET - Etiopia 3
GE - Georgia 3
MT - Malta 3
SN - Senegal 3
TT - Trinidad e Tobago 3
BY - Bielorussia 2
CR - Costa Rica 2
DO - Repubblica Dominicana 2
HU - Ungheria 2
KW - Kuwait 2
LU - Lussemburgo 2
MD - Moldavia 2
TH - Thailandia 2
AF - Afghanistan, Repubblica islamica di 1
AO - Angola 1
AQ - Antartide 1
BA - Bosnia-Erzegovina 1
BS - Bahamas 1
BW - Botswana 1
CI - Costa d'Avorio 1
CY - Cipro 1
EE - Estonia 1
GP - Guadalupe 1
GY - Guiana 1
HR - Croazia 1
KG - Kirghizistan 1
LV - Lettonia 1
MK - Macedonia 1
Totale 20.373
Città #
Singapore 1.781
San Jose 1.029
Chandler 959
Dublin 785
Jacksonville 740
Ashburn 573
Dallas 422
Beijing 360
Princeton 319
Southend 294
Los Angeles 242
Nanjing 220
Izmir 212
The Dalles 194
Santa Clara 192
Munich 188
Pescara 179
Ann Arbor 178
Council Bluffs 175
Ho Chi Minh City 161
New York 161
Chieti 159
Wilmington 144
Dearborn 134
Hanoi 124
Altamura 121
Boardman 119
Cambridge 109
Tongling 91
Buffalo 89
Hong Kong 78
Moscow 74
Nanchang 71
São Paulo 68
Helsinki 67
Brussels 59
Woodbridge 58
Redondo Beach 54
Dong Ket 50
Orem 50
Rome 49
Tokyo 46
Vienna 44
Warsaw 39
Amsterdam 37
Milan 37
Nuremberg 37
Montreal 36
Brooklyn 35
Chicago 35
Denver 35
Houston 35
Shenyang 34
Atlanta 33
Hebei 33
Brno 32
Ancona 31
Da Nang 30
Frankfurt am Main 30
Norwalk 30
Kunming 29
London 29
Boston 28
Tianjin 28
Chennai 27
St Louis 27
Jiaxing 26
Turku 26
Hefei 25
Johannesburg 25
Falls Church 24
Seattle 23
Stockholm 23
Washington 23
Changsha 21
Haiphong 21
Ascoli Piceno 19
Baghdad 18
Hangzhou 18
Manchester 18
Poplar 18
Rio de Janeiro 18
Toronto 18
Mexico City 17
Montesilvano 17
San Francisco 17
Hyderabad 15
Belo Horizonte 14
Düsseldorf 14
Lappeenranta 14
Mumbai 14
Seoul 14
Tashkent 14
Campinas 13
Grevenbroich 13
Kraków 13
Lanzhou 13
Pune 13
San Mateo 13
Brasília 12
Totale 12.573
Nome #
Developing a Decision-making Model Based on an Interdisciplinary Oncological Care Group for the Management of Colorectal Cancer 279
A phase I study of recombinant interferon-alpha administered as a seven-day continuous venous infusion at circadian-rhythm modulated rate in patients with cancer. 211
Circulating Cancer Stem Cell-Derived Extracellular Vesicles as a Novel Biomarker for Clinical Outcome Evaluation 192
90K (Mac-2 BP) and galectins in tumor progression and metastasis. 184
CD19.CAR-T cell-derived extracellular vesicles express CAR and kill leukemic cells, contributing to antineoplastic therapy 181
Breast cancer "tailored follow-up" in Italian oncology units: A web-based survey 180
Impact of BMI on clinical outcome in advanced cancer patients treated with anti‑PD‑1 Immune checkpoint inhibitors: a preliminary analysis 178
A comparative study of the antiinflammatory, anticoagulant, antiangiogenic, and antiadhesive activities of nine different fucoidans from brown seaweeds 176
CAR-T-Derived Extracellular Vesicles: A Promising Development of CAR-T Anti-Tumor Therapy 172
Allergooncology: an expanding research area 172
A phase II study of dose-dense epirubicin plus cyclophosphamide followed by docetaxel plus capecitabine and pegfilgrastim support as preoperative therapy for patients with stage II, IIIA breast cancer. 167
Neoadjuvant chemotherapy in triple-negative breast cancer: A multicentric retrospective observational study in real-life setting 167
Combination of peripheral neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio is predictive of pathological complete response after neoadjuvant chemotherapy in breast cancer patients 166
The 90K tumor associated antigen and clinical progression in human immunodeficiency virus infection 162
ERBB3 BINDING ANTIBODY 161
A Case of Stage I Vulvar Squamous Cell Carcinoma with Early Relapse and Rapid Disease Progression 159
Prognostic relevance of LGALS3BP in human colorectal carcinoma 159
Gli analoghi sintetici delle glicoamine come potenziali nuovi farmaci nella prevenzione delle metastasi 158
Exosomes as pleiotropic players in pancreatic cancer 158
Effects of repurposed drug candidates nitroxoline and nelfinavir as single agents or in combination with erlotinib in pancreatic cancer cells 156
A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable 156
90K (Mac-2 BP) predicts CD4 decline in human immunodeficiency virus-infected patients with CD4 counts above 200 x 10^6 cells/L 155
Occupational allergy: is there a role for nanoparticles? 154
Blood Circulating CD133+ Extracellular Vesicles Predict Clinical Outcomes in Patients with Metastatic Colorectal Cancer 153
90k is a serum marker of poor-prognosis in non-hodgkins-lymphoma patients. 150
High Blood Concentration of Leukocyte-Derived Extracellular Vesicles Is Predictive of Favorable Clinical Outcomes in Patients with Pancreatic Cancer: Results from a Multicenter Prospective Study 149
Elevated serum levels of 90K/MAC-2BP predict unresponsiveness to alfa-interferon therapy in chronic HCV hepatitis patients 148
A novel serum test using interferon for early detection of tumor reccurrence in cancer patients after radical surgery. 148
The 90K protein increases major histocompatibility complex class I expression and is regulated by hormones, gamma-interferon, and double-strand polynucleotides. 148
The Benzimidazole-Based Anthelmintic Parbendazole: A Repurposed Drug Candidate That Synergizes with Gemcitabine in Pancreatic Cancer 148
Purification and characterization of a 90 kDa protein releasedfrom human tumors and tumor cell lines 147
Effect of Gender on the Outcome of Patients Receiving Immune Checkpoint Inhibitors for Advanced Cancer: A Systematic Review and Meta-Analysis of Phase III Randomized Clinical Trials 146
A PHASE II STUDY OF NEOADJUVANT CHEMOTHERAPY WITH CISTAPLIN, EPIRUBICIN AND VP – 16 FOR STAGE III UNRESECTABLE NON-SMALL CELL LUNG CANCER 145
An Epigenetic Approach to Pancreatic Cancer Treatment: the Prospective Role of Histone Deacetylase Inhibitors 144
New Targets for Therapy in Pancreatic Cancer 144
High expression of 90K (Mac-2 BP) is associated with poor survival in node-negative breast cancer patients not receiving adjuvant systemic therapies 144
Long-term outcome of neoadjuvant systemic therapy for locally advanced breast cancer in routine clinical practice. 142
Multi-omics staging of locally advanced rectal cancer predicts treatment response: a pilot study 140
Glicomimetici quali potenziali nuovi farmaci per la prevenzione delle metastasi. 140
A 90-kDa protein serum marker for the prediction of progression to AIDS in a cohort of HIV-1+ homosexual men. 140
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial 137
An FPSE-HPLC-PDA method for the determination of anticancer drugs in human whole blood, plasma, and urine 136
A perspective analysis: microRNAs, glucose metabolism, and drug resistance in colon cancer stem cells 136
Novel inhibitors of pvhl-elongin c binding 135
Upstream stimulatory factor regulates constitutive expression and hormonal suppression of the 90K (Mac-2BP) protein. 134
Inhibition of tumor growth and angiogenesis by SP-2, an anti-LGALS3BP antibody 134
Trop-2, Na+/K+ ATPase, CD9, PKCα, cofilin assemble a membrane signaling super-complex that drives colorectal cancer growth and invasion 134
Long-term outcome of neoadjuvant endocrine therapy with aromatase inhibitors in elderly women with hormone receptor-positive breast cancer 133
A Stochastic Model for the HIV/AIDS Dynamic Evolution 132
Inhibition of tumor growth and angiogenesis by SP-2, an anti-lectin, galactoside-binding soluble 3 binding protein (LGALS3BP) antibody. 132
BIOLOGICAL INDICATORS OF PROGNOSIS IN HUMAN CANCER: AN EMERGING ROLE FOR LECTIN GALACTOSIDE-BINDING SOLUBLE 3-BINDING PROTEIN (LGALS3BP) 132
PLC-gamma-1 phosphorylation status is prognostic of metastatic risk in patients with early-stage Luminal-A and -B breast cancer subtypes 132
Optimizing the Choice for Adjuvant Chemotherapy in Gastric Cancer 130
Elevated serum levels of a 90,000 daltons tumor-associated antigen in cancer and in infection by human immunodeficiency virus (HIV). 130
Adhesion to 90K (Mac-2 BP) as a mechanism for lymphoma drug resistance in vivo. 129
Weighing the role of skeletal muscle mass and muscle density in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: a multicenter real-life study 128
Changes of topoisomerase IIalpha expression in breast tumors after neoadjuvant chemotherapy predicts relapse-free survival 127
Chronomodulated infusion of cisplatin, 5-fluorouracil and folinic acid: lack of activity in advanced colorectal cancer. 127
A Flow cytometric study of early gastric cancer 126
Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: A real-world experience 126
Flow Cytometry Detection of Anthracycline-Treated Breast Cancer Cells: An Optimized Protocol 125
TGF-β-1 increases 90K tumor associated antigen gene expression by increasing upstream regulatory factor binding to the minimal promoter. 125
Outcomes of HER2-positive early breast cancer patients in the pre-trastuzumab and trastuzumab eras: a real-world multicenter observational analysis. The RETROHER study 125
Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting 125
Do cut-off values of lymph node ratio and presence of perineural invasion affect survival in breast cancer patients with pathologic N3a lymph node stage? Reply to Kadri Altundag 124
Weight loss and body mass index in advanced gastric cancer patients treated with second-line ramucirumab: a real-life multicentre study 124
Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study 124
Sunitinib malate (SU-11248) alone or in combination with low-dose docetaxel inhibits the growth of DU-145 prostate cancer xenografts. 123
The 2EF Antibody Targets a Unique N-Terminal Epitope of Trop-2 and Enhances the In Vivo Activity of the Cancer-Selective 2G10 Antibody 122
Principali effetti collaterali delle terapie mediche 122
DNA ploidy and S-phase fraction in pulmonary carcinoids. 121
Tumor-derived microvesicles: The metastasomes. 121
Corrigendum to "Circulating Cancer Stem Cell-Derived Extracellular Vesicles as a Novel Biomarker for Clinical Outcome Evaluation" 121
Prognostic value of 90K protein in HIV infection 120
Expression of the 90K tumor-associated protein in benign and malignant melanocytic lesions. 120
Palliative radiotherapy in advanced cancer patients treated with immune-checkpoint inhibitors: The PRACTICE study 120
Tgf-β1 transcriptionally promotes 90K expression: possible implications for cancer progression 120
Predictive value of skeletal muscle mass for immunotherapy with nivolumab in non-small cell lung cancer patients: A “hypothesis-generator” preliminary report 119
Identification of Subgroups of Early Breast Cancer Patients at High Risk of Nonadherence to Adjuvant Hormone Therapy: Results of an Italian Survey 118
Drug repurposing, an attractive strategy in pancreatic cancer treatment: Preclinical and clinical updates 118
Role of 90K protein in asthma and TH2-type cytokine expression. 117
Long-term outcome of breast cancer patients with pathologic N3a lymph node stage 117
Alectinib induced regression of renal and hepatic cysts caused by crizotinib 117
Concentrations of Galectin-3 in the Sera of Normal Controls and Cancer Patients 116
Unknown primary tumors 116
Lack of prognostic value of immunohistochemical determination of epidermal growth-factor receptors in human prostate-cancer. 115
Prognostic value of a novel circulating serum 90K antigen in breast cancer 114
Synthetic lactulose amines: novel class of anticancer agents that induce tumor-cell apoptosis and inhibit galectin-mediated homotypic cell aggregation and endothelial cell morphogenesis. 114
LGALS3BP, A TUMOR-ASSOCIATED ANTIGEN, UPREGULATES VEGF IN HUMAN BREAST CANCER: POSSIBLE IMPLICATIONS IN ANGIOGENESIS 114
Prognostic value of gender and primary tumor location in metastatic colon cancer 114
Prognostic value of a novel circulating serum 90K antigen in HIV-infected haemophilia patients. 113
An ErbB-3 antibody, MP-RM-1, inhibits tumor growth by blocking ligand-dependent and independent activation of ErbB-3/Akt signaling. 113
Timed flat infusion of 5-fluorouracil increases the tolerability of 5-fluorouracil/docetaxel regimen in metastatic breast cancer: a dose-finding study. 112
Relief of symptoms after gefitinib is associated with improvement of rest/activity rhythm in advanced lung cancer 112
Persistence and adherence to androgen deprivation therapy in men with prostate cancer: an administrative database study 111
Combinations of biological response modifiers: rationale and clinical responses. 110
A stochastic model for evaluating the HIV anti-retroviral treatment patient cost: a case study 110
3D-informed targeting of the Trop-2 signal-activation site drives selective cancer vulnerability 109
Lack of expression of galectin-3 is associated with a poor outcome in node-negative patients with laryngeal squamous-cell carcinoma. 109
EV20, a Novel Anti-ErbB-3 Humanized Antibody, Promotes ErbB-3 Down-Regulation and Inhibits Tumor Growth In Vivo. 109
Totale 13.808
Categoria #
all - tutte 82.104
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 82.104


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202191 0 0 0 0 0 0 0 0 0 0 0 91
2021/2022891 35 22 15 174 78 37 35 69 59 22 94 251
2022/20232.683 216 341 202 307 267 483 147 236 300 22 103 59
2023/20241.415 121 46 79 63 85 457 236 54 41 40 15 178
2024/20253.722 178 606 501 105 87 184 344 237 357 216 392 515
2025/20267.357 599 320 802 846 702 464 1.202 420 747 667 404 184
Totale 21.088